Skip to main content
Top
Published in: Rheumatology International 11/2010

01-09-2010 | Case Report

Lupus myocarditis: marked improvement in cardiac function after intravenous immunoglobulin therapy

Authors: Vikas Suri, Subhash Varma, Kiran Joshi, Pankaj Malhotra, Savita Kumari, Sanjay Jain

Published in: Rheumatology International | Issue 11/2010

Login to get access

Abstract

Intravenous immunoglobulin (IVIg) is emerging as the mainstay in the treatment of many autoimmune diseases, including systemic lupus erythematosus. IVIg has been found to be beneficial in myocarditis due to dermatomyositis/polymyositis, Kawasaki disease, and viral myocarditis in children. We report an 18-year-old man of active lupus with worsening cardiac systolic function who did not respond to pulse methylprednisolone and cyclophosphamide, but subsequently showed an improvement in his cardiac function after IVIg administration.
Literature
1.
go back to reference Moder KG, Miller TD, Tazelaar HD (1999) Cardiac involvement in systemic lupus erythematosus. Mayo Clin Proc 74:275–284CrossRefPubMed Moder KG, Miller TD, Tazelaar HD (1999) Cardiac involvement in systemic lupus erythematosus. Mayo Clin Proc 74:275–284CrossRefPubMed
2.
go back to reference Borenstein DG, Fye WB, Arnett FC, Stevens MB (1978) The myocarditis of systemic lupus erythematosus: association with myositis. Ann Intern Med 89:619–624PubMed Borenstein DG, Fye WB, Arnett FC, Stevens MB (1978) The myocarditis of systemic lupus erythematosus: association with myositis. Ann Intern Med 89:619–624PubMed
3.
go back to reference Routray SN, Mishra TK, Patnaik UK, Behera M (2004) Myocarditis as an initial manifestation of systemic lupus erythematosus. J Assoc Physicians India 52:673–674PubMed Routray SN, Mishra TK, Patnaik UK, Behera M (2004) Myocarditis as an initial manifestation of systemic lupus erythematosus. J Assoc Physicians India 52:673–674PubMed
4.
go back to reference Meier WP, Gordon DS, Howard RF, Saleh MN, Miller SB, Lieberman JD, Woodlee PM (1990) Intravenous immunoglobulin therapy in systemic lupus erythematosus associated-thrombocytopenia. Arthritis Rheum 33:1233–1239CrossRef Meier WP, Gordon DS, Howard RF, Saleh MN, Miller SB, Lieberman JD, Woodlee PM (1990) Intravenous immunoglobulin therapy in systemic lupus erythematosus associated-thrombocytopenia. Arthritis Rheum 33:1233–1239CrossRef
5.
go back to reference Monova D, Belovezhdov N, Altunkova I, Monov S (2002) Intravenous immunoglobulin G in the treatment of patients with chronic glomerulonephritis: clinical experience lasting 15 years. Nephron 90:262–266CrossRefPubMed Monova D, Belovezhdov N, Altunkova I, Monov S (2002) Intravenous immunoglobulin G in the treatment of patients with chronic glomerulonephritis: clinical experience lasting 15 years. Nephron 90:262–266CrossRefPubMed
7.
go back to reference Sherer Y, Levy Y, Fabrizzi F, Shoenfeld Y (1999) Immunomodulation of various autoimmune diseases by intravenous immunoglobulin. Drugs Today (Barc) 35:513–518 Sherer Y, Levy Y, Fabrizzi F, Shoenfeld Y (1999) Immunomodulation of various autoimmune diseases by intravenous immunoglobulin. Drugs Today (Barc) 35:513–518
8.
go back to reference Yoshikawa H, Nomura Y, Masuda K, Hazeki D, Yotsumoto K, Arata M et al (2006) Four cases of Kawasaki syndrome complicated with myocarditis. Circ J 70:202–205CrossRefPubMed Yoshikawa H, Nomura Y, Masuda K, Hazeki D, Yotsumoto K, Arata M et al (2006) Four cases of Kawasaki syndrome complicated with myocarditis. Circ J 70:202–205CrossRefPubMed
9.
go back to reference Drucker NA, Colan SD, Lewis AB, Beiser AS, Wessel DL, Takahashi M et al (1994) Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation 89:252–257PubMed Drucker NA, Colan SD, Lewis AB, Beiser AS, Wessel DL, Takahashi M et al (1994) Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation 89:252–257PubMed
10.
go back to reference Seite Jean-François, Shoenfeld Yehuda, Youinou Pierre, Hillion Sophie (2008) What is the contents of the magic draft IVIg? Autoimmun Rev 7:435–439CrossRefPubMed Seite Jean-François, Shoenfeld Yehuda, Youinou Pierre, Hillion Sophie (2008) What is the contents of the magic draft IVIg? Autoimmun Rev 7:435–439CrossRefPubMed
11.
go back to reference Sherer Y, Levy Y, Shoenfeld Y (1999) Marked improvement of severe cardiac dysfunction after one course of intravenous immunoglobulin in a patient with systemic lupus erythematosus. Clin Rheumatol 18:238–240CrossRefPubMed Sherer Y, Levy Y, Shoenfeld Y (1999) Marked improvement of severe cardiac dysfunction after one course of intravenous immunoglobulin in a patient with systemic lupus erythematosus. Clin Rheumatol 18:238–240CrossRefPubMed
12.
go back to reference Disla E, Rhim HR, Reddy A, Ramaprasad S, Taranta A (1993) Reversible cardiogenic shock in a patient with lupus myocarditis. J Rheumatol 20:2174PubMed Disla E, Rhim HR, Reddy A, Ramaprasad S, Taranta A (1993) Reversible cardiogenic shock in a patient with lupus myocarditis. J Rheumatol 20:2174PubMed
13.
go back to reference Micheloud D, Calderón M, Caparrros M, D’Cruz DP (2007) Intravenous immunoglobulin therapy in severe lupus myocarditis: good outcome in three patients. Ann Rheum Dis 66:986–987CrossRefPubMed Micheloud D, Calderón M, Caparrros M, D’Cruz DP (2007) Intravenous immunoglobulin therapy in severe lupus myocarditis: good outcome in three patients. Ann Rheum Dis 66:986–987CrossRefPubMed
Metadata
Title
Lupus myocarditis: marked improvement in cardiac function after intravenous immunoglobulin therapy
Authors
Vikas Suri
Subhash Varma
Kiran Joshi
Pankaj Malhotra
Savita Kumari
Sanjay Jain
Publication date
01-09-2010
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 11/2010
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-1098-x

Other articles of this Issue 11/2010

Rheumatology International 11/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.